Trial Profile
Phase II/III Randomized Placebo-Controlled Trial of Arimoclomol in SOD1 Positive Familial ALS Amyotrophic Lateral Sclerosis (ALS).
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Arimoclomol (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Therapeutic Use
- 24 Jan 2018 According to an Orphazyme media release, results were published in in the peer-reviewed clinical journal Neurology.
- 10 Aug 2017 Status changed from active, no longer recruiting to completed.
- 04 Nov 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2016 as reported by ClinicalTrials.gov.